EX M
LIVE

Serial Number

99067235

Owner

Expedition Medicines, Inc.

Attorney

Christina M. Licursi

Filing Date

Mar 4, 2025

Add to watchlist:

No watchlists yet
View on USPTO

EX M Trademark

Serial Number: 99067235

EX M is a trademark filed by Expedition Medicines, Inc. on March 4, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Expedition Medicines, Inc. (2 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

March 4, 2025

Registration Date

Not Registered

Published for Opposition

June 16, 2026

Goods & Services

Software as a service (SAAS) services featuring software using artificial intelligence for use in the fields of healthcare for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; software as a service (SAAS) services featuring software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules and chemical structures; software as a service (SAAS) services featuring software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; providing temporary use of on-line non-downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; scientific research, namely, research and analysis services for the design and characterization of chemical and biologic therapeutic products; research services in the fields of genomic, transcriptomic, and proteomic analysis; genomic and proteomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; DNA analysis and sequencing services for scientific and research purposes; research, development and consultancy in the field of genomics and proteomics; medical research, namely, compiling data for research purposes in the field of genomics and proteomics; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; platform as a service (PaaS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, and meta-transcriptomics

Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders

Downloadable software for use in the pharmaceuticals and healthcare fields, namely, for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable software for providing life science analytics

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 10, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 20, 2026 CNSA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 25, 2026 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 17, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 17, 2025 GNSL
SUSPENSION LETTER WRITTEN
Oct 17, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 16, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 16, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Aug 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Aug 8, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 6, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 25, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Mar 4, 2025 MAFR
NEW APPLICATION ENTERED
Mar 4, 2025 NWAP